Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Market Access Biosimilars Australia

Australia: Easier & Faster Mechanisms To Drive Biosimilars Uptake

  • News

Executive Summary

It will soon become easier to prescribe a number of medicines for rheumatoid arthritis and plaque psoriasis in Australia.

You may also be interested in...



Australian ‘Uptake Drivers’ For Boosting Biosimilar Prescribing Start With Etanercept

Biosimilars are being given a boost in Australia through the use of “uptake drivers” to encourage doctors to prescribe a biosimilars in preference to the reference product. The first product involved is etanercept.

French Regulator At Odds With EMA Over Safety Restrictions For Pseudoephedrine

The product information for all pseudoephedrine-containing medicines in the EU will need to be updated, the European Medicines Agency said.

French Regulator At Odds With EMA Over Safety Restrictions For Pseudoephedrine

The product information for all pseudoephedrine-containing medicines in the EU will need to be updated, the European Medicines Agency said today.

Table

View full table

Topics

Related Companies

Tags:
Market Access Biosimilars Australia
Latest Headlines

US FDA’s Marks Willing To Accept Gene Therapies Occasionally Not Confirming Benefit

FDA Is ‘Getting More Aggressive’ In Going After Drug Efficacy Claims Outside Label

BIO’s New CEO Is Biotech Industry Veteran With Compelling Family Story, Ready To Take On The IRA

Patient-Focused Listening Sessions For Medicare-Negotiated Drugs: Key Takeaways From Round One

See All
UsernamePublicRestriction

Register

PS149085

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By